A new drug discovered through an analysis collaboration between the University at Buffalo and Tetra Therapeutics could shield against memory loss, nerve injury, and different symptoms of Alzheimer’s disease. The preclinical analysis discovered that the drug – known as BPN14770 – deters the results of amyloid-beta, a trademark protein of Alzheimer’s that’s toxic to nerve cells.
Latest research discovers Alzheimer’s could develop without dementia in practically 25% of wholesome 80-year-old patients, suggesting the body could turn to compensatory mechanisms to keep up the nervous system.
BPN14770, beneath development by Tetra Therapeutics, might assist activate these mechanisms that help nerve health and prevent dementia, even with the progression of Alzheimer’s.
Its benefits might also translate to Fragile X syndrome, developmental disabilities, and schizophrenia, researchers say.
“Such observations imply that the brain may tolerate Alzheimer’s pathology to some extent as a result of compensatory mechanisms working at the cellular and synaptic ranges,” stated Ying Xu, MD, Ph.D., co-lead investigator, and research affiliate professor within the UB School of Pharmacy and Pharmaceutical Sciences.
“Our new research means that BPN14770 may be able to activate several biological mechanisms that protect the mind from memory deficits, neuronal damage, and biochemical impairments.”
The study, revealed on Sept. 5 in the Journal of Pharmacology and Experimental Therapeutics, was also led by James M. O’Donnell, Ph.D., dean, and professor of the UB School of Pharmacy and Pharmaceutical Sciences. Mark E. Gurney, Ph.D., chairman, and chief executive officer of Tetra Therapeutics, based in Grand Rapids, Michigan, collaborated on the research.